Kerman University of Medical Sciences

Document Type: Original Article

Authors

1 Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran

2 Department of Biostatistics, School of Health Sciences, Mazandaran University of Medical Sciences, Sari, Iran

Abstract

Background: Methamphetamine (MA) abuse is a serious and costly public health problem worldwide; It also commonly affects the sleep quality. The present study was carried out aiming to evaluate the effectiveness of modafinil versus placebo on sleep pattern in MA withdrawal during an eight-week period. Methods: In a double-blind randomized controlled study, a total of 80 patients with a confirmed diagnosis MA withdrawal were treated with modafinil (200 mg/day). Pittsburgh Sleep Quality Index (PSQI) and Epworth sleepiness scale (ESS) were used to assess sleep pattern in the 1th and 56th days of the study. Analysis of covariance (ANCOVA) was applied to compare the groups. All analyses were performed by using SPSS software with a 5% significance level. Findings: The mean age of the people in the intervention and placebo groups was 32.92 ± 2.06 and 34.08 ± 2.13 years, respectively. The mean scores of ESS decreased from 16.15 ± 4.50 to 9.15 ± 3.34 after the intervention in the modafinil group (P < 0.001), with no significant reduction in the placebo group (P = 0.990). The mean scores of PSQI decreased from 13.88 ± 3.40 to 9.92 ± 3.10 after the intervention in the modafinil group (P < 0.001), however there was no significant reduction in the placebo group (P = 0.980). The value of the Eta effect size of the PSQI and ESS questionnaires was 0.52 and 0.72, respectively. Modafinil was superior to placebo in improving the PSQI and ESS scales in the 56th day of assessment (P < 0.050). Conclusion: Modafinil improves the sleep quality in patients with MA withdrawal.

Keywords

1. Rezaei F, Emami M, Zahed S, Morabbi MJ, Farahzadi M, Akhondzadeh S. Sustained-release methylphenidate in methamphetamine dependence treatment: A double-blind and placebo-controlled trial. Daru 2015; 23: 2.
2. Alemikhah M, Faridhosseini F, Kordi H, Rasouli-Azad M, Shahini N. Comparative study of the activity of brain behavioral systems in methamphetamine and opiate dependents. Int J High Risk Behav Addict 2016; 5(1): e25075.
3. Lashkaripour K, Torbati E. Methamphetamine
dependency. Int J High Risk Behav Addict 2012; 1(1): 7-8.
4. Alam-mehrjerdi Z, Mokri A, Dolan K. Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country. Asian J Psychiatr 2015; 16: 17-25.
5. Ekhtiari H, Alam-Mehrjerdi Z, Hassani-Abharian P, Nouri M, Farnam R, Mokri A. Examination and evaluation of craving-inductive verbal cues among Persian-speaking methamphetamine abusers. Adv Cogn Sci 2010; 12(2): 69-82.
Proof Version
Effects of Modafinil on Sleep Pattern during MA Withdrawal Moosavi et al.
170 Addict Health, Summer 2019; Vol 11, No 3
http://ahj.kmu.ac.ir, 06 July
6. Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict 2004; 13(3): 248-55.
7. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: A focused review. Br J Clin Pharmacol 2010; 69(6): 578-92.
8. Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2012; 120(1-3): 135-41.
9. Heinzerling KG, Swanson AN, Kim S, Cederblom L, Moe A, Ling W, et al. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2010; 109(1-3): 20-9.
10. Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 2009; 104(2): 224-33.
11. Hester R, Lee N, Pennay A, Nielsen S, Ferris J. The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence. Exp Clin Psychopharmacol 2010; 18(6): 489-97.
12. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1996; 93(24): 14128-33.
13. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 1998; 241(2-3): 95-8.
14. Engber TM, Dennis SA, Jones BE, Miller MS, Contreras PC. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: Comparison with amphetamine. Neuroscience 1998; 87(4): 905-11.
15.Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology (Berl) 2002; 159(3): 238-47.
16.Wesensten NJ, Killgore WD, Balkin TJ. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 2005; 14(3): 255-66.
17. Buguet A, Montmayeur A, Pigeau R, Naitoh P. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. II. Effects on two
nights of recovery sleep. J Sleep Res 1995; 4(4): 229-41.
18. Chapotot F, Pigeau R, Canini F, Bourdon L, Buguet A. Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG. Psychopharmacology (Berl) 2003; 166(2): 127-38.
19.McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: A comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008; 35(3): 334-42.
20. Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993; 103(1): 30-6.
21. Sadeghniiat HK, Montazeri A, Khajeh MA, Aminian O, Rahimi GA, Saraei M, et al. The Epworth Sleepiness Scale: translation and validation study of the Iranian version. Sleep Breath 2013; 17(1): 419-26.
22. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989; 28(2): 193-213.
23. Farrahi MJ, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P). Sleep Breath 2012; 16(1): 79-82.
24. First MB. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). Washington, DC: American Psychiatric Publishing Inc.; 1997.
25. Sharifi V, Assadi SM, Mohammadi MR, Amini H, Kaviani H, Semnani Y, et al. A Persian translation of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: Psychometric properties. Compr Psychiatry 2009; 50(1): 86-91.
26. Sugden C, Housden CR, Aggarwal R, Sahakian BJ, Darzi A. Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: A randomized controlled trial. Ann Surg 2012; 255(2): 222-7.
27. Nicholson AN, Belyavin AJ, Pascoe PA. Modulation of rapid eye movement sleep in humans by drugs that modify monoaminergic and purinergic transmission. Neuropsychopharmacology 1989; 2(2): 131-43.
28. James LM, Iannone R, Palcza J, Renger JJ, Calder N, Cerchio K, et al. Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berl) 2011; 215(4): 643-53.
29. Bodenmann S, Xu S, Luhmann UF, Arand M, Berger W, Jung HH, et al. Pharmacogenetics of Proof Version
Effects of Modafinil on Sleep Pattern during MA Withdrawal Moosavi et al.
Addict Health, Summer 2019; Vol 11, No 3 171
http://ahj.kmu.ac.ir, 06 July
modafinil after sleep loss: catechol-O-methyltransferase genotype modulates waking functions but not recovery sleep. Clin Pharmacol Ther 2009; 85(3): 296-304.
30. Bodenmann S, Landolt HP. Effects of modafinil on the sleep EEG depend on Val158Met genotype of COMT. Sleep 2010; 33(8): 1027-35.
31. Turner C, Belyavin AJ, Nicholson AN. Duration of activity and mode of action of modafinil: Studies on sleep and wakefulness in humans. J Psychopharmacol 2014; 28(7): 643-54.
32. Schwartz JR, Feldman NT, Fry JM, Harsh J. Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Sleep Med 2003; 4(1): 43-9.
33.Makris AP, Rush CR, Frederich RC, Kelly TH. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004; 42(2): 185-95.
34.Morgan PT, Pace-Schott E, Pittman B, Stickgold R, Malison RT. Normalizing effects of modafinil on sleep in chronic cocaine users. Am J Psychiatry 2010; 167(3): 331-40.
35. Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009; 104(1-2): 133-9.
36. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30(1): 205-11.
37. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008; 33(4): 761-8.
38. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009; 301(11): 1148-54.